Evaluating spoken language as a biomarker for automated screening of cognitive impairment.

backgroundTimely and accurate assessment of cognitive impairment remains a major unmet need. Speech biomarkers offer a scalable, non-invasive, cost-effective solution for automated screening. However, the clinical utility of machine learning (ML) remains limited by interpretability and generalisability to real-world speech datasets.

methodsWe evaluate explainable ML for screening of Alzheimer's disease and related dementias (ADRD) and severity prediction using benchmark DementiaBank speech (N = 291, 64% female, 69.8 ± 8.6 years). We validate generalisability on pilot data collected in-residence (N = 22, 59% female, 76.2 ± 8.0 years). To enhance clinical utility, we stratify risk for actionable triage and assess linguistic feature importance.

resultsWe show that a Random Forest trained on linguistic features for ADRD detection achieves a mean sensitivity of 69.4% (95% confidence interval (CI) = 66.4-72.5) and specificity of 83.3% (78.0-88.7). On pilot data, this model yields a mean sensitivity of 70.0% (58.0-82.0) and specificity of 52.5% (39.3-65.7). For prediction of Mini-Mental State Examination (MMSE) scores, a Random Forest Regressor achieves a mean absolute MMSE error of 3.7 (3.7-3.8), with comparable performance of 3.3 (3.1-3.5) on pilot data. Risk stratification improves specificity by 13% on the test set, offering a pathway for clinical triage. Linguistic features associated with ADRD include increased use of pronouns and adverbs, greater disfluency, reduced analytical thinking, lower lexical diversity, and fewer words that reflect a psychological state of completion.

conclusionsOur predictive modelling shows promise for integration with conversational technology at home to monitor cognitive health and triage higher-risk individuals, enabling early screening and intervention.